American Cancer Society. (2017, August 1). Immunotherapy for Kidney Cancer. Extrait de: https://www.cancer.org/cancer/kidney-cancer/treating/immunotherapy.html.
American Society of Clinical Oncology. (2017, August). Kidney Cancer: Treatment Options. Extrait de: https://www.cancer.net/cancer-types/kidney-cancer/treatment-options.
Drugs and Health Products, Health Canada. (2018, July 5). Regulatory Decision Summary: Opdivo. Extrait de: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00382.
Lane BR, Canter DJ, Rin BL, et al. Cancer of the kidney. DeVita VT Jr, Lawrence TS, Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Édition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 63:865-884.
National Cancer Institute. (2018, April 5). Renal Cell Cancer Treatment (PDQ®) Health Professional Version. Extrait de: https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq.
Pal SK, Reckamp K, Yu H, et al. Immunotherapy in the management of renal cell carcinoma. Scardino PT, Lineham WM, Zelefsky MJ & Vogelzang NJ (eds.). (2011). Comprehensive Textbook of Genitourinary Oncology. (4th Édition). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 45C: pp. 788-795.
Reaume MN, Basappa NS, Wood L, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. (2017). Canadian Urological Association Journal. 11(10):310-320. Extrait de: https://www.kidneycancercanada.ca/media/1173779/2017-management-of-advanced-kidney-cancer.pdf.×